Yoon‐Koo Kang

Research interests

Publications

• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00620-7

• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2100070

• Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(21)00692-6

• Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

  British Journal of Cancer · 2020 · https://doi.org/10.1038/s41416-020-0802-1

• Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

  JAMA Oncology · 2020 · https://doi.org/10.1001/jamaoncol.2020.4564

• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30937-9

• Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30481-9

• Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31827-5

• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31046-2

• Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30111-0

• Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

  Investigational New Drugs · 2016 · 10.1007/s10637-016-0407-y

• The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

  Gastric Cancer · 2015 · 10.1007/s10120-015-0526-8

• Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.54.3298

• SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.53.7746

• Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

  JAMA · 2014 · 10.1001/jama.2014.7189

• Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.45.8372

• Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.3009

• Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70102-5

• Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.39.9824

• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61857-1

• Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.36.2236

• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61121-x

• Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

  Annals of Oncology · 2009 · 10.1093/annonc/mdn717

• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(08)70285-7

• Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization

  Journal of Biological Chemistry · 1997 · 10.1074/jbc.272.27.17118

Current projects

No projects listed.